Patient Information Leaflet
Verquvo 2.5mg film-coated tablets
Verquvo 5mg film-coated tablets
Verquvo 10mg film-coated tablets
vericiguat
This medicinal product is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack
Verquvo contains the active substance vericiguat, which is a type of heart medicine called a soluble guanylate cyclase stimulator.
Verquvo is used to treat adults with long-term heart failure who have recently experienced an increase in symptoms of heart failure. You may have been hospitalized and/or received a medicine (diuretic) given into a vein to help you urinate more than usual.
Heart failure occurs when the heart is weak and cannot pump enough blood to the body. Common symptoms of heart failure include difficulty breathing, tiredness, or swelling caused by fluid buildup.
Do not take Verquvo
If any of these conditions apply to you, talk to your doctorbefore taking this medicine.
Warnings and precautions
Tell your doctor or pharmacist before you start taking Verquvo if you have
Children and adolescents
Do not give this medicine to children or adolescents under 18 years of age, as it has not been studied in this age group yet.
Other medicines and Verquvo
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, especially medicines that
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Pregnancy
Verquvo should not be used during pregnancy, as it is not known if it can harm the fetus. If you can become pregnant, ask your doctor about reliable contraceptive methods.
Breastfeeding
It is not known if Verquvo passes into breast milk or if it can harm your baby. Your doctor will decide with you whether to stop breastfeeding or treatment with Verquvo.
Driving and using machines
If you feel dizzy during treatment with this medicine, do not drive vehicles, ride bicycles, or use machines.
Verquvo contains lactose and sodium
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The recommended initial dose is 1tablet of 2.5mgonce a day. Your doctor will then adjust the dose based on how well you tolerate the treatment. Usually, your doctor will increase the dose after about 2 weeks to 1 tablet of 5 mg once a day and after about another 2 weeks to the maximum target dose of 1tablet of 10mgonce a day.
If you have low blood pressureduring treatment with Verquvo, this may make you feel dizzy and lightheaded, and your doctor may temporarily reduce your dose of Verquvo or stop your treatment with Verquvo.
Take one tablet at the same time every day with food. If you cannot swallow the tablet, you can crush Verquvo and mix it with water. Take this mixture immediately.
If you take more Verquvo than you should
Consult your doctor immediately if you take more Verquvo than you should and experience any of the side effects listed in section 4. The most likely effect would be a drop in blood pressure, which can make you feel dizzy and lightheaded.
If you forget to take Verquvo
Take the missed tablet as soon as you remember on the same day as the missed dose. Do not take a double dose to make up for the missed tablet.
If you stop taking Verquvo
Do not stop taking this medicine without talking to your doctor first. If you stop taking this medicine, your condition may worsen.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Possible side effects are:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on each blister or bottle after "EXP". The expiry date is the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Verquvo
Appearance of the product and pack contents
Verquvo 2.5 mg film-coated tablets (tablets) are round, biconvex, and white with a diameter of 7 mm, marked with "2.5" on one side and "VC" on the other.
Verquvo 5 mg film-coated tablets (tablets) are round, biconvex, and reddish-brown with a diameter of 7 mm, marked with "5" on one side and "VC" on the other.
Verquvo 10 mg film-coated tablets (tablets) are round, biconvex, and yellow-orange with a diameter of 9 mm, marked with "10" on one side and "VC" on the other.
Verquvo is available
Not all pack sizes may be marketed.
Marketing authorisation holder
Bayer AG
51368 Leverkusen
Germany
Manufacturer
Bayer AG
Kaiser-Wilhelm-Allee
51368 Leverkusen
Germany
For further information about this medicine, please contact the local representative of the marketing authorisation holder:
Belgium Bayer SA-NV Tel: +32-(0)2-535 63 11 | Lithuania UAB Bayer Tel: +37 05 23 36 868 |
Bulgaria Bayer EAD Tel: +359 02 4247280 | Luxembourg Bayer SA-NV Tel: +32-(0)2-535 63 11 |
Czech Republic Bayer s.r.o. Tel: +420 266 101 111 | Hungary Bayer Hungária KFT Tel: +36 14 87-41 00 |
Denmark Bayer A/S Tel: +45 45 23 50 00 | Malta Alfred Gera and Sons Ltd. Tel: +35 621 44 62 05 |
Germany Bayer Vital GmbH Tel: +49 (0)214-30 513 48 | Netherlands Bayer B.V. Tel: +31-(0)297-28 06 66 |
Estonia Bayer OÜ Tel: +372 655 8565 | Norway Bayer AS Tel: +47 23 13 05 00 |
Greece Bayer Ελλάς ΑΒΕΕ Tel: +30-210-61 87 500 | Austria Bayer Austria Ges.m.b.H. Tel: +43-(0)1-711 46-0 |
Spain Bayer Hispania S.L. Tel: +34-93-495 65 00 | Poland Bayer Sp. z o.o. Tel: +48 22 572 35 00 |
France Bayer HealthCare Tel (Green number): +33-(0)800 87 54 54 | Portugal Bayer Portugal, Lda. Tel: +351 21 416 42 00 |
Croatia Bayer d.o.o. Tel: +385-(0)1-6599 900 | Romania SC Bayer SRL Tel: +40 21 529 59 00 |
Ireland Bayer Limited Tel: +353 1 216 3300 | Slovenia Bayer d. o. o. Tel: +386 (0)1 58 14 400 |
Iceland Icepharma hf. Tel: +354 540 8000 | Slovakia Bayer spol. s r.o. Tel: +421 2 59 21 31 11 |
Italy Bayer S.p.A. Tel: +39 02 397 8 1 | Finland Bayer Oy Tel: +358- 20 785 21 |
Cyprus NOVAGEM Limited Tel: +357 22 48 38 58 | Sweden Bayer AB Tel: +46 (0) 8 580 223 00 |
Latvia SIA Bayer Tel: +371 67 84 55 63 | United Kingdom (Northern Ireland) Bayer AG Tel: +44-(0)118 206 3000 |
Date of last revision of this leaflet:
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.